Shanghai Haohai Biological Technology Co (SHSE:688366) ROCE %: 6.82% (As of Mar. 2026)


SHSE:688366 Shanghai Haohai Biological Technology Co Ltd SHSE:688366
69 GF Score
Price ¥28.61
GF Value ¥43.53
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co ROCE %?

Shanghai Haohai Biological Technology Co SHSE:688366 -3.57% 69 ROCE % is 6.82% as of Mar. 2026. GuruFocus rates SHSE:688366 with a GF Score™ of 69/100 and a GF Value™ of ¥43.53 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shanghai Haohai Biological Technology Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.82%.

Shanghai Haohai Biological Technology Co  (SHSE:688366) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shanghai Haohai Biological Technology Co ROCE % Related Terms

Shanghai Haohai Biological Technology Co ROCE % Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co ROCE % Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.29 3.79 8.07 7.66 4.28

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.62 0.00 7.29 -6.40 6.82
SHSE:688366
69GF Score
Shanghai Haohai Biological Technology Co Ltd SHSE:688366
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co ROCE % Calculation

Shanghai Haohai Biological Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=258.123/( ( (7121.392 - 865.893) + (6720.063 - 914.671) )/ 2 )
=258.123/( (6255.499+5805.392)/ 2 )
=258.123/6030.4455
=4.28 %

Shanghai Haohai Biological Technology Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=394.22/( ( (6720.063 - 914.671) + (6666.309 - 908.501) )/ 2 )
=394.22/( ( 5805.392 + 5757.808 )/ 2 )
=394.22/5781.6
=6.82 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.82% mean?
Shanghai Haohai Biological Technology Co (SHSE:688366) has a ROCE % of 6.82% as of Mar. 2026.
Is Shanghai Haohai Biological Technology Co's ROCE % too high?
Shanghai Haohai Biological Technology Co's current ROCE % is 6.82%. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's ROCE % compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's ROCE % of 6.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Shanghai Haohai Biological Technology Co's current ROCE % is 6.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (SHSE:688366) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥43.53, compared to a current price of ¥28.61 — trading 34.3% below its estimated fair value. The current ROCE % is 6.82%. Shanghai Haohai Biological Technology Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (SHSE:688366), the current ROCE % is 6.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (SHSE:688366) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of ¥28.61 is trading 34.3% below its estimated GF Value™ of ¥43.53. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for SHSE:688366:

  • ROCE %: 6.82%
  • GF Value™: ¥43.53 vs. price of ¥28.61 (34.3% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688366 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong5HB:Germany
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
69GF Score

Get the complete analysis for SHSE:688366

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.61
Price
¥43.53
GF Value